Combination chemotherapy of 5-fluorouracil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan.
BACKGROUND
Combination therapy consisting of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been shown to be effective in the treatment of gastric cancer.


METHODS
The efficacy and safety of the combination therapy consisting of 5-FU and low-dose CDDP were assessed in 37 patients with advanced or recurrent gastric cancer. One course consisted of continuous drip infusion of 5-FU (330 mg/m2/day) on days 1-5 (7) + 5-day drip infusion of CDDP (5 mg/m2/day) for 4 weeks. The patients were treated with at least one course.


RESULTS
The complete response (CR) + partial response (PR) rate was 35.1% and median survival-time (MST) was 7.1 months. There were no grade 3 or more adverse effects.


CONCLUSIONS
Our results suggest that this mode of combination therapy leads to a fairly favorable outcome with few adverse effects in patients with advanced and recurrent gastric cancer.
Enjoji
Akihito
A
Department of Surgery II, Nagasaki University School of Medicine, Japan. aenjoji@net.nagasaki-u.ac.jp
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*; D015996:Survival Rate
D002945:Cisplatin; D005472:Fluorouracil